421 related articles for article (PubMed ID: 33524419)
1. Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection.
Huang L; Wan J; Wu Y; Tian Y; Yao Y; Yao S; Ji X; Wang S; Su Z; Xu H
Life Sci; 2021 Apr; 270():119142. PubMed ID: 33524419
[TBL] [Abstract][Full Text] [Related]
2. Crossing the blood-brain barrier with AAV vectors.
Liu D; Zhu M; Zhang Y; Diao Y
Metab Brain Dis; 2021 Jan; 36(1):45-52. PubMed ID: 33201426
[TBL] [Abstract][Full Text] [Related]
3. Exosome-associated AAV vector as a robust and convenient neuroscience tool.
Hudry E; Martin C; Gandhi S; György B; Scheffer DI; Mu D; Merkel SF; Mingozzi F; Fitzpatrick Z; Dimant H; Masek M; Ragan T; Tan S; Brisson AR; Ramirez SH; Hyman BT; Maguire CA
Gene Ther; 2016 Apr; 23(4):380-92. PubMed ID: 26836117
[TBL] [Abstract][Full Text] [Related]
4. BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment.
Chen W; Yao S; Wan J; Tian Y; Huang L; Wang S; Akter F; Wu Y; Yao Y; Zhang X
J Control Release; 2021 May; 333():129-138. PubMed ID: 33775685
[TBL] [Abstract][Full Text] [Related]
5.
Batista AR; King OD; Reardon CP; Davis C; Shankaracharya ; Philip V; Gray-Edwards H; Aronin N; Lutz C; Landers J; Sena-Esteves M
Hum Gene Ther; 2020 Jan; 31(1-2):90-102. PubMed ID: 31696742
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.
Saraiva J; Nobre RJ; Pereira de Almeida L
J Control Release; 2016 Nov; 241():94-109. PubMed ID: 27637390
[TBL] [Abstract][Full Text] [Related]
7. Customized blood-brain barrier shuttle peptide to increase AAV9 vector crossing the BBB and augment transduction in the brain.
Zhang X; Chai Z; Lee Dobbins A; Itano MS; Askew C; Miao Z; Niu H; Samulski RJ; Li C
Biomaterials; 2022 Feb; 281():121340. PubMed ID: 34998171
[TBL] [Abstract][Full Text] [Related]
8. AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.
Liguore WA; Domire JS; Button D; Wang Y; Dufour BD; Srinivasan S; McBride JL
Mol Ther; 2019 Nov; 27(11):2018-2037. PubMed ID: 31420242
[TBL] [Abstract][Full Text] [Related]
9.
Marcó S; Haurigot V; Bosch F
Hum Gene Ther; 2019 Oct; 30(10):1211-1221. PubMed ID: 31482754
[TBL] [Abstract][Full Text] [Related]
10. Context-Specific Function of the Engineered Peptide Domain of PHP.B.
Martino RA; Fluck EC; Murphy J; Wang Q; Hoff H; Pumroy RA; Lee CY; Sims JJ; Roy S; Moiseenkova-Bell VY; Wilson JM
J Virol; 2021 Sep; 95(20):e0116421. PubMed ID: 34346767
[TBL] [Abstract][Full Text] [Related]
11. Widespread transduction of astrocytes and neurons in the mouse central nervous system after systemic delivery of a self-complementary AAV-PHP.B vector.
Rincon MY; de Vin F; Duqué SI; Fripont S; Castaldo SA; Bouhuijzen-Wenger J; Holt MG
Gene Ther; 2018 Apr; 25(2):83-92. PubMed ID: 29523880
[TBL] [Abstract][Full Text] [Related]
12. Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration.
Zhang X; He T; Chai Z; Samulski RJ; Li C
Biomaterials; 2018 Sep; 176():71-83. PubMed ID: 29860139
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E, low-density lipoprotein receptor, and immune cells control blood-brain barrier penetration by AAV-PHP.eB in mice.
Xie BS; Wang X; Pan YH; Jiang G; Feng JF; Lin Y
Theranostics; 2021; 11(3):1177-1191. PubMed ID: 33391529
[No Abstract] [Full Text] [Related]
14. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain.
Matsuzaki Y; Konno A; Mochizuki R; Shinohara Y; Nitta K; Okada Y; Hirai H
Neurosci Lett; 2018 Feb; 665():182-188. PubMed ID: 29175632
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Sialic Acid Dependence Influences the Central Nervous System Transduction Profile of Adeno-associated Viruses.
Albright BH; Simon KE; Pillai M; Devlin GW; Asokan A
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894463
[TBL] [Abstract][Full Text] [Related]
16. More expansive gene transfer to the rat CNS: AAV PHP.EB vector dose-response and comparison to AAV PHP.B.
Dayton RD; Grames MS; Klein RL
Gene Ther; 2018 Aug; 25(5):392-400. PubMed ID: 30013186
[TBL] [Abstract][Full Text] [Related]
17. AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges.
Kang L; Jin S; Wang J; Lv Z; Xin C; Tan C; Zhao M; Wang L; Liu J
J Control Release; 2023 Mar; 355():458-473. PubMed ID: 36736907
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Dexamethasone Administration for Maintaining Global Transduction Efficacy of Adeno-Associated Virus Serotype 9.
Chai Z; Zhang X; Dobbins AL; Rigsbee KM; Wang B; Samulski RJ; Li C
Hum Gene Ther; 2019 Jul; 30(7):829-840. PubMed ID: 30700148
[TBL] [Abstract][Full Text] [Related]
19. Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration.
Chai Z; Zhang X; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2018 Sep; 286():415-424. PubMed ID: 30107215
[TBL] [Abstract][Full Text] [Related]
20. Adeno-Associated Virus (AAV) Vectors in the CNS.
McCown TJ
Curr Gene Ther; 2011 Jun; 11(3):181-8. PubMed ID: 21453285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
